Mohammad Krayem

1.1k total citations
27 papers, 716 citations indexed

About

Mohammad Krayem is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Mohammad Krayem has authored 27 papers receiving a total of 716 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Molecular Biology, 14 papers in Oncology and 6 papers in Immunology. Recurrent topics in Mohammad Krayem's work include Melanoma and MAPK Pathways (12 papers), Cancer-related Molecular Pathways (6 papers) and Cutaneous Melanoma Detection and Management (4 papers). Mohammad Krayem is often cited by papers focused on Melanoma and MAPK Pathways (12 papers), Cancer-related Molecular Pathways (6 papers) and Cutaneous Melanoma Detection and Management (4 papers). Mohammad Krayem collaborates with scholars based in Belgium, France and Canada. Mohammad Krayem's co-authors include Ahmad Awada, Fabrice Journé, Ahmad Najem, Ghanem Ghanem, Ghanem E. Ghanem, Dominique Bron, Nathalie Meuleman, Mehdi Najar, Laurence Lagneaux and Sven Saussez and has published in prestigious journals such as Cancer Research, Frontiers in Immunology and European Journal of Cancer.

In The Last Decade

Mohammad Krayem

27 papers receiving 708 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mohammad Krayem Belgium 16 414 290 145 128 111 27 716
Robert McKinstry United States 13 475 1.1× 435 1.5× 98 0.7× 105 0.8× 98 0.9× 21 971
Marisol González-Huarriz Spain 14 419 1.0× 314 1.1× 73 0.5× 103 0.8× 237 2.1× 25 734
Dongmei Fan China 16 321 0.8× 361 1.2× 177 1.2× 133 1.0× 66 0.6× 54 751
Caner Saygin United States 10 426 1.0× 337 1.2× 79 0.5× 87 0.7× 181 1.6× 27 767
Alice Agliano Spain 12 431 1.0× 429 1.5× 100 0.7× 99 0.8× 246 2.2× 16 810
Manoj M. Pillai United States 18 557 1.3× 231 0.8× 141 1.0× 133 1.0× 236 2.1× 39 897
Amit J. Sabnis United States 13 562 1.4× 245 0.8× 101 0.7× 86 0.7× 113 1.0× 32 951
Kelly C. Goldsmith United States 19 543 1.3× 237 0.8× 150 1.0× 149 1.2× 165 1.5× 48 911
Jennifer Sims‐Mourtada United States 16 515 1.2× 529 1.8× 113 0.8× 66 0.5× 153 1.4× 34 1.0k

Countries citing papers authored by Mohammad Krayem

Since Specialization
Citations

This map shows the geographic impact of Mohammad Krayem's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mohammad Krayem with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mohammad Krayem more than expected).

Fields of papers citing papers by Mohammad Krayem

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mohammad Krayem. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mohammad Krayem. The network helps show where Mohammad Krayem may publish in the future.

Co-authorship network of co-authors of Mohammad Krayem

This figure shows the co-authorship network connecting the top 25 collaborators of Mohammad Krayem. A scholar is included among the top collaborators of Mohammad Krayem based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mohammad Krayem. Mohammad Krayem is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Najem, Ahmad, Mohammad Krayem, Fabrice Journé, et al.. (2023). Targeting Prohibitins to Inhibit Melanoma Growth and Overcome Resistance to Targeted Therapies. Cells. 12(14). 1855–1855. 5 indexed citations
2.
Najem, Ahmad, Fabrice Journé, Ahmad Awada, et al.. (2023). The benefit of co-targeting PARP-1 and c-Met on the efficacy of radiotherapy in wild type BRAF melanoma. Frontiers in Medicine. 10. 1149918–1149918. 4 indexed citations
3.
Verset, Laurine, et al.. (2023). The current understanding of the immune landscape relative to radiotherapy across tumor types. Frontiers in Immunology. 14. 1148692–1148692. 12 indexed citations
4.
Journé, Fabrice, Géraldine Descamps, Sven Saussez, et al.. (2022). Restoring p53 Function in Head and Neck Squamous Cell Carcinoma to Improve Treatments. Frontiers in Oncology. 11. 799993–799993. 41 indexed citations
5.
Krayem, Mohammad, Ahmad Najem, François Salès, et al.. (2021). Dasatinib Stimulates Its Own Mechanism of Resistance by Activating a CRTC3/MITF/Bcl-2 Pathway in Melanoma with Mutant or Amplified c-Kit. Molecular Cancer Research. 19(7). 1221–1233. 4 indexed citations
6.
Najem, Ahmad, Jasper Wouters, Mohammad Krayem, et al.. (2021). Tyrosine-Dependent Phenotype Switching Occurs Early in Many Primary Melanoma Cultures Limiting Their Translational Value. Frontiers in Oncology. 11. 780654–780654. 8 indexed citations
7.
Rouas, Rédouane, Ghanem E. Ghanem, Philippe Martinive, et al.. (2021). Humanized Mice as a Valuable Pre-Clinical Model for Cancer Immunotherapy Research. Frontiers in Oncology. 11. 784947–784947. 70 indexed citations
8.
Krayem, Mohammad, Nadège Kindt, Ahmad Najem, et al.. (2021). Abstract 1082: Regorafenib resistance is associated with senescence-like phenotype and EMT in colorectal cancer (CRC). Cancer Research. 81(13_Supplement). 1082–1082. 1 indexed citations
9.
Najem, Ahmad, et al.. (2021). RTK Inhibitors in Melanoma: From Bench to Bedside. Cancers. 13(7). 1685–1685. 31 indexed citations
10.
Krayem, Mohammad, Philippe Aftimos, Ahmad Najem, et al.. (2020). Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance. Cancers. 12(2). 512–512. 15 indexed citations
11.
Krayem, Mohammad, Ahmad Najem, Ghanem E. Ghanem, et al.. (2020). Metabolic Reprogramming in Metastatic Melanoma with Acquired Resistance to Targeted Therapies: Integrative Metabolomic and Proteomic Analysis. Cancers. 12(5). 1323–1323. 16 indexed citations
12.
Krayem, Mohammad, Ahmad Najem, An Wouters, et al.. (2019). The Benefit of Reactivating p53 under MAPK Inhibition on the Efficacy of Radiotherapy in Melanoma. Cancers. 11(8). 1093–1093. 20 indexed citations
13.
Najar, Mehdi, Mohammad Krayem, Makram Merimi, et al.. (2018). Insights into inflammatory priming of mesenchymal stromal cells: functional biological impacts. Inflammation Research. 67(6). 467–477. 69 indexed citations
14.
Krayem, Mohammad, Ahmad Najem, Thierry Cresteil, et al.. (2018). Targeting prohibitin with small molecules to promote melanogenesis and apoptosis in melanoma cells. European Journal of Medicinal Chemistry. 155. 880–888. 31 indexed citations
15.
16.
Najem, Ahmad, Mohammad Krayem, François Salès, et al.. (2017). P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition. European Journal of Cancer. 83. 154–165. 41 indexed citations
17.
Najem, Ahmad, Mohammad Krayem, Anne Perdrix, et al.. (2017). New Drug Combination Strategies in Melanoma: Current Status and Future DirectionsNew Drug Combination Strategies in Melanoma: Current Status and Future Directions. Anticancer Research. 37(11). 5941–5953. 28 indexed citations
18.
Krayem, Mohammad, Fabrice Journé, Murielle Wiedig, et al.. (2016). p53 Reactivation by PRIMA-1Met (APR-246) sensitises V600E/KBRAF melanoma to vemurafenib. European Journal of Cancer. 55. 98–110. 45 indexed citations
19.
Krayem, Mohammad, et al.. (2016). GLI inhibitor GANT61 kills melanoma cells and acts in synergy with obatoclax. International Journal of Oncology. 49(3). 953–960. 21 indexed citations
20.
Krayem, Mohammad, Fabrice Journé, Murielle Wiedig, et al.. (2014). Prominent role of cyclic adenosine monophosphate signalling pathway in the sensitivity of WTBRAF/WTNRAS melanoma cells to vemurafenib. European Journal of Cancer. 50(7). 1310–1320. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Robert McKinstry Breakdown of academic impact, for papers by Marisol González-Huarriz Breakdown of academic impact, for papers by Dongmei Fan Breakdown of academic impact, for papers by Caner Saygin Breakdown of academic impact, for papers by Alice Agliano Breakdown of academic impact, for papers by Manoj M. Pillai Breakdown of academic impact, for papers by Amit J. Sabnis Breakdown of academic impact, for papers by Kelly C. Goldsmith Breakdown of academic impact, for papers by Jennifer Sims‐Mourtada
Rankless by CCL
2026